BlackRock Technology and Private Equity Term Trust (BTX) Stock Analysis

Sector: FINANCIAL SERVICES - ASSET MANAGEMENT

Exchange: NYSE

Key Metrics

• Price: $6.59
• Market Cap: $1.43B
• P/E Ratio: 55.92
• EPS: $0.12
• 52-Week High: $7.05
• 52-Week Low: $4.57

About BlackRock Technology and Private Equity Term Trust

Brooklyn ImmunoTherapeutics, Inc. (BTX) is a clinical-stage biopharmaceutical company headquartered in Brooklyn, New York, specializing in the development of cutting-edge cellular and genetic therapies for cancer treatment. Leveraging its proprietary technology platforms, the company is committed to addressing critical unmet medical needs in oncology. With a strong focus on research and development, Brooklyn ImmunoTherapeutics aims to improve patient outcomes and enhance the quality of life f...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for BlackRock Technology and Private Equity Term Trust and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does BTX pay dividends?

BlackRock Technology and Private Equity Term Trust (BTX) does not currently pay a regular dividend.

What is BTX's P/E ratio?

BlackRock Technology and Private Equity Term Trust has a price-to-earnings (P/E) ratio of 55.92.

What is BTX's market cap?

BlackRock Technology and Private Equity Term Trust (BTX) has a market capitalization of $1.43B with a current stock price of $6.59.